Therapeutic indications

Ambrisentan is indicated for:

Pulmonary arterial hypertension (PAH) classified as WHO functional class II and III

Population group: both men and women, only adults (18 years old or older)

Ambrisentan is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 5-10 mg once daily


Ambrisentan is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV





Idiopathic pulmonary fibrosis

Other interstitial pulmonary diseases with fibrosis

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines